Details
This analysis evaluates the association between glucagon-like peptide-1 receptor agonists (GLP-1 RA), sodium-glucose cotransporter-2 inhibitors (SGLT-2), or dipeptidyl peptidase-4 inhibitors (DPP-4) and intentional self-harm in individuals with evidence of diabetes, or diabetes and obesity, in the Sentinel Distributed Database (SDD). In this report, we identified individuals with incident use of GLP-1 RA (exposure), SGLT-2i (comparator), or DPP-4 (comparator), and we evaluated the association between these products and intentional self-harm using inverse probability of treatment weighting (IPTW) to adjust for confounding.
The study period includes data from October 1, 2015, to September 30, 2023. We distributed this request to ten Sentinel Data Partners on May 1, 2024.
The analytic packages associated with this analysis can be found externally in Sentinel's Git Repository located here. The Git Repository serves as Sentinel's version control tracking system for analytic packages and technical documentation.